An Open-label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Trial Profile

An Open-label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs GDC 0810 (Primary) ; Palbociclib
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Genentech; Seragon Pharmaceuticals
  • Most Recent Events

    • 23 Jun 2017 The trial has been completed in Spain
    • 25 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 23 Dec 2016 Results (n=30) related to 18F-fluoroestradiol PET/CT as a biomarker of estrogen receptor (ER) in phase I part of the trial was published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top